tezosentan has been researched along with vasoactive intestinal peptide in 1 studies
| Studies (tezosentan) | Trials (tezosentan) | Recent Studies (post-2010) (tezosentan) | Studies (vasoactive intestinal peptide) | Trials (vasoactive intestinal peptide) | Recent Studies (post-2010) (vasoactive intestinal peptide) |
|---|---|---|---|---|---|
| 157 | 29 | 33 | 10,873 | 123 | 1,221 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albu, G; Beghetti, M; Fontao, F; Habre, W; Janosi, TZ; Petak, F; von Ungern-Sternberg, BS | 1 |
1 other study(ies) available for tezosentan and vasoactive intestinal peptide
| Article | Year |
|---|---|
Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension.
Topics: Administration, Oral; Airway Resistance; Analysis of Variance; Animals; Antihypertensive Agents; Blood Pressure; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchoconstriction; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelins; Hypertension, Pulmonary; Iloprost; Infusion Pumps, Implantable; Infusions, Parenteral; Lung; Lung Volume Measurements; Male; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Piperazines; Prostaglandins I; Purines; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Endothelin; Signal Transduction; Sildenafil Citrate; Sulfones; Tetrazoles; Time Factors; Vasoactive Intestinal Peptide; Vasodilator Agents | 2011 |